


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (original) A compound of the formula I:



I

wherein:

Ar is phenyl which is unsubstituted or substituted with 1-5 of R3, wherein R3 is independently selected from the group consisting of:

- (1) halogen,
- (2) C1-6alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,
- (3) OC1-6alkyl, which is linear or branched and is unsubstituted or substituted with 1-5 halogens,
- (4) CN, and
- (5) OH;

R1 and R2 are independently selected from the group consisting of:

- (1) hydrogen,
- (2) CN,
- (3) C1-10alkyl, which is linear or branched and which is unsubstituted or substituted with:
  - (a) halogen, or

(b) phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R<sup>4</sup>, OR<sup>4</sup>, NSO<sub>2</sub>R<sup>4</sup>, N(C<sub>1</sub>-6alkyl)SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, NR<sup>7</sup>R<sup>8</sup>, CONR<sup>7</sup>R<sup>8</sup>, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched,

(4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R<sup>4</sup>, OR<sup>4</sup>, NSO<sub>2</sub>R<sup>4</sup>, N(C<sub>1</sub>-6alkyl)SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, NR<sup>7</sup>R<sup>8</sup>, CONR<sup>7</sup>R<sup>8</sup>, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched,

(5) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, halogen, NO<sub>2</sub>, CN, OH, R<sup>4</sup>, OR<sup>4</sup>, NSO<sub>2</sub>R<sup>4</sup>, N(C<sub>1</sub>-6alkyl)SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, NR<sup>7</sup>R<sup>8</sup>, CONR<sup>7</sup>R<sup>8</sup>, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched,

(6) C<sub>3</sub>-6cycloalkyl, which is optionally substituted with 1-5 substituents independently selected from halogen, OH, C<sub>1</sub>-6alkyl, and OC<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl and OC<sub>1</sub>-6alkyl are linear or branched and optionally substituted with 1-5 halogens,

(7) OH,

(8) OR<sup>4</sup>, and

(9) NR<sup>7</sup>R<sup>8</sup>;

R<sup>4</sup> is C<sub>1</sub>-6alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 groups independently selected from halogen, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched;

R<sup>5</sup>, R<sup>6</sup> and R<sup>9</sup> are independently selected from the group consisting of:

(1) hydrogen,

(2) C<sub>1</sub>-10alkyl, which is linear or branched and which is unsubstituted or substituted with one or more substituents selected from:

(a) halogen,

(b) hydroxy,

- (c) phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, OH, C<sub>1</sub>-6alkyl, and OC<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched and optionally substituted with 1-5 halogens,
- (d) naphthyl, wherein the naphthyl is optionally substituted with 1-5 substituents independently selected from halogen, OH, C<sub>1</sub>-6alkyl, and OC<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched and optionally substituted with 1-5 halogens,
- (e) CO<sub>2</sub>H,
- (f) CO<sub>2</sub>C<sub>1</sub>-6alkyl,
- (g) CONR<sup>7</sup>R<sup>8</sup>,
- (3) CN,
- (4) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from C<sub>1</sub>-6alkyl, OC<sub>1</sub>-6alkyl, hydroxy and halogen, wherein the C<sub>1</sub>-6alkyl is linear or branched and optionally substituted with 1-5 halogens,
- (5) naphthyl which is unsubstituted or substituted with 1-5 substituents independently selected from C<sub>1</sub>-6alkyl, OC<sub>1</sub>-6alkyl, hydroxy and halogen, wherein the C<sub>1</sub>-6alkyl is linear or branched and optionally substituted with 1-5 halogens,
- (6) CO<sub>2</sub>H,
- (7) CO<sub>2</sub>C<sub>1</sub>-6alkyl,
- (8) CONR<sup>7</sup>R<sup>8</sup>, and
- (9) C<sub>3</sub>-6cycloalkyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, OH, C<sub>1</sub>-6alkyl, and OC<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched and optionally substituted with 1-5 halogens;

R<sup>7</sup> and R<sup>8</sup> are independently selected from the group consisting of:

- (1) hydrogen,
- (2) phenyl, which is unsubstituted or substituted with substituents independently selected from halogen, OH, C<sub>1</sub>-6alkyl, and OC<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched and optionally substituted with 1-5 halogens,

(3) C<sub>3</sub>-6cycloalkyl, which is unsubstituted or substituted with substituents independently selected from halogen, OH, C<sub>1</sub>-6alkyl, and OC<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched and optionally substituted with 1-5 halogens, and


(4) C<sub>1</sub>-6alkyl, which is linear or branched and which is unsubstituted or substituted with:

(a) halogen, or

(b) phenyl, which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, OH, C<sub>1</sub>-6alkyl, and OC<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched and optionally substituted with 1-5 halogens, or wherein R<sup>7</sup> and R<sup>8</sup> together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is unsubstituted or substituted with one to five substituents independently selected from halogen, hydroxy, C<sub>1</sub>-6 alkyl, and C<sub>1</sub>-6 alkoxy, wherein alkyl and alkoxy are unsubstituted or substituted with one to five halogens;

or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.


2. (original) The compound of Claim 1 of the formula Ia:



Ia

wherein Ar, R<sup>1</sup>, R<sup>2</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>9</sup> are defined in Claim 1;  
or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.


3. (original) The compound of Claim 1 of the formula Ib:



Ib

wherein Ar, R<sup>1</sup>, R<sup>2</sup> and R<sup>5</sup> are defined in Claim 1;  
or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.


4. (original) The compound of Claim 1 of the formula Ic:



Ic

wherein Ar, R<sup>1</sup> and R<sup>5</sup> are defined in Claim 1;  
or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof..


5. (original) The compound of Claim 1 of the formula Id:



Id

wherein Ar and R<sup>1</sup> are defined in Claim 1;  
or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof..

6. (original) The compound of Claim 1 of the formula Ie:



Ie

wherein Ar, R<sup>1</sup> and R<sup>2</sup> are defined in Claim 1;  
or a pharmaceutically acceptable salt thereof or an individual diastereomer thereof..

7. (original) The compound of Claim 1 wherein Ar is phenyl which is unsubstituted or substituted with 1-5 of R<sup>3</sup> which are independently selected from the group consisting of:

- (1) fluoro,
- (2) chloro,
- (3) bromo,
- (4) methyl,
- (5) CF<sub>3</sub>, and
- (6) OH.

8. (original) The compound of Claim 1 wherein Ar is selected from the group consisting of:

- (1) phenyl,
- (2) 2-fluorophenyl,
- (3) 3,4-difluorophenyl,
- (4) 2,5-difluorophenyl, and
- (5) 2,4,5-trifluorophenyl.

9. (original) The compound of Claim 1 wherein R<sup>1</sup> is selected from the group consisting of:

- (1) hydrogen,

- (2) C<sub>1</sub>-6alkyl, which is linear or branched and which is unsubstituted or substituted with phenyl or 1-5 fluoro,
- (3) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, CN, OH, R<sup>4</sup>, OR<sup>4</sup>, NHSO<sub>2</sub>R<sup>4</sup>, N(C<sub>1</sub>-6alkyl)SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, NR<sup>7</sup>R<sup>8</sup>, CONR<sup>7</sup>R<sup>8</sup>, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched,
- (4) a 5- or 6-membered heterocycle which may be saturated or unsaturated comprising 1-4 heteroatoms independently selected from N, S and O, the heterocycle being unsubstituted or substituted with 1-3 substituents independently selected from oxo, halogen, NO<sub>2</sub>, CN, OH, R<sup>4</sup>, OR<sup>4</sup>, NHSO<sub>2</sub>R<sup>4</sup>, N(C<sub>1</sub>-6alkyl)SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, NR<sup>7</sup>R<sup>8</sup>, CONR<sup>7</sup>R<sup>8</sup>, CO<sub>2</sub>H, and CO<sub>2</sub>C<sub>1</sub>-6alkyl, wherein the C<sub>1</sub>-6alkyl is linear or branched,
- (5) C<sub>3</sub>-6cycloalkyl, and
- (6) NR<sup>7</sup>R<sup>8</sup>.

10. (original) The compound of Claim 1 wherein R<sup>1</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2) CF<sub>3</sub>,
- (3) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, methyl, CF<sub>3</sub>, OCF<sub>3</sub>, NHSO<sub>2</sub>Me, NHSO<sub>2</sub>CF<sub>3</sub>, SO<sub>2</sub>Me, SO<sub>2</sub>CF<sub>3</sub>, SO<sub>2</sub>NH<sub>2</sub>, NH<sub>2</sub>, NHMe, NMe<sub>2</sub>, and CONH<sub>2</sub>,
- (4) pyridine, pyrazine, and imidazole which is unsubstituted or substituted with 1-5 substituents independently selected from CF<sub>3</sub>, Me, and NO<sub>2</sub>,
- (5) cyclopropyl,
- (6) morpholine,
- (7) NH<sub>2</sub>,
- (8) NHMe,
- (9) NMe<sub>2</sub>, and
- (10) NHCH<sub>2</sub>Ph.

11. (original) The compound of Claim 1 wherein R<sup>1</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2) CF<sub>3</sub>,
- (3) phenyl which is unsubstituted or substituted with 1-5 substituents independently selected from halogen, methyl, CF<sub>3</sub>, OCF<sub>3</sub>, NHO<sub>2</sub>Me, SO<sub>2</sub>Me, SO<sub>2</sub>CF<sub>3</sub>, SO<sub>2</sub>NH<sub>2</sub>, and CONH<sub>2</sub>,
- (4) pyridine, pyrazine, or imidazole which is unsubstituted or substituted with 1-5 substituents independently selected from CF<sub>3</sub>, Me, and NO<sub>2</sub>, and
- (5) cyclopropyl.

12. (original) The compound of Claim 1 wherein R<sup>1</sup> is hydrogen or CF<sub>3</sub>.

13. (original) The compound of Claim 1 wherein R<sup>2</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2) C<sub>1-6</sub>alkyl, which is linear or branched and which is unsubstituted or substituted with 1-5 fluoro,
- (3) OH,
- (4) OR<sup>4</sup>, and
- (5) NR<sup>7</sup>R<sup>8</sup>.

14. (original) The compound of Claim 1 wherein R<sup>2</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2) OH,
- (3) methoxy,
- (4) isopropoxy,
- (5) CF<sub>3</sub>,
- (6) NH<sub>2</sub>, and
- (7) NHMe.

15. (original) The compound of Claim 1 wherein R<sup>2</sup> is hydrogen.

16. (original) The compound of Claim 1 wherein R<sup>5</sup>, R<sup>6</sup> and R<sup>9</sup> are independently selected from the group consisting of:

- (1) hydrogen, and
- (2) C<sub>1-10</sub>alkyl, which is linear or branched and which is unsubstituted or substituted with one or more substituents selected from:
  - (a) halogen, and
  - (b) phenyl, wherein the phenyl is optionally substituted with 1-5 substituents independently selected from halogen, OH, C<sub>1-6</sub>alkyl, and OC<sub>1-6</sub>alkyl, wherein the C<sub>1-6</sub>alkyl and OC<sub>1-6</sub>alkyl are linear or branched and optionally substituted with 1-5 halogens.





17. (original) The compound of Claim 1 wherein R<sup>5</sup>, R<sup>6</sup> and R<sup>9</sup> are independently selected from the group consisting of:

- (1) hydrogen,
- (2) CH<sub>3</sub>, and
- (3) CH<sub>2</sub>-phenyl.





18. (original) The compound of Claim 1 wherein R<sup>5</sup> is H or CH<sub>3</sub> and R<sup>6</sup> and R<sup>9</sup> are hydrogen.




19. (original) A compound which is selected from the group consisting of:

Serial No.: 10/520,839  
Case No.: 21139YP  
Page No.: 11



Serial No.: 10/520,839  
Case No.: 21139YP  
Page No.: 12





or a pharmaceutically acceptable salt thereof.

20. (original) A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

21-39. (cancelled)

40. (new) A method of treating Type diabetes comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Claim 1